Kronos Bio, Inc. operates as a biotechnology company. The Company discovers and develops therapies that modulate historically recalcitrant cancer targets. Kronos Bio serves customers in worldwide.

Current Report (Form 8-K | Period ending 2025-06-20)

Current Report (Form 8-K | Period ending 2025-06-04)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kronos Bio (KRON US)

Current Report (Form 8-K | Period ending 2025-06-20)

Current Report (Form 8-K | Period ending 2025-06-04)

Quarterly Report (Form 10-Q | Period ending 2025-03-31)

SC14D9C | Written communication by the subject company relating to a third party tender offer

Current Report (Form 8-K | Period ending 2025-05-01)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)